Jazz Pharmaceuticals launch of Vyxeos in EU may produce upside, say BMO Capital

BMO Capital analyst Gary Nachman kept his Outperform rating and $206 price target on Jazz Pharmaceuticals after its webcast today to discuss the recent approval of Vyxeos for acute myeloid leukemia in Europe. The analyst notes that the regulatory action could be a “source of upside” given that the size of high-risk AML market in the region is the same as that of the U.S. Nachman expects Vyxeos to remain a “key long-term growth driver” for the company.
https://thefly.com/landingPageNews.php?id=2792307